MedTrace Logo

A Cross-Sectional Study of Serum Levels of Adipocytokines in Children With Febrile Seizures

NCT04967066 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-10-04

No results posted yet for this study

Summary

Febrile seizure (FS) is a common neurological condition in children, affecting 2 - 14% of children. FS is defined as seizures occurring in a child aged from six months to five years that is accompanied by a fever (≥38°C) without central nervous system infection. FS is classified into simple febrile seizure (SFS) and complex febrile seizure (CFS). SFS accounts for 70-75% of FS cases and is characterized by being generalized, duration of less than 15 minutes, occurs once in 24 hours, and no previous neurologic problems. We aim to investigate serum levels of adipocytokines, specifically leptin, adiponectin, and IL-6, in children with FS.

Conditions

  • Febrile Seizure

Interventions

DIAGNOSTIC_TEST

Serum Levels of Adipocytokines

Serum leptin and adiponectin: venous blood samples (3 ml) will be obtained from children with FS (within 3 hours of seizures) as well as the two control groups. The serum will be obtained by centrifugation at 3,500 rpm for 5 min at 4 ℃. The serum will be immediately separated and stored at -70 ℃. Serum leptin and adiponectin will be assessed through enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Abdelrahim A. Sadek, Professor · Sohag University

  • Abdelhady R. Abdel-Gawad, Lecturer · Sohag University

  • Elsayed M. Abdelkreem, Lecturer · Sohag University

Eligibility

Min Age
6 Months
Max Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-23
Primary Completion
2022-09-23
Completion
2022-10-02

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04967066 on ClinicalTrials.gov